# GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma

> **NCT01655628** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Stage IV Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)
- **DRUG:** GC chemotherapy (Gemcitabine, Cisplatin)

## Key facts

- **NCT ID:** NCT01655628
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2014-07
- **Final completion:** 2014-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01655628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01655628, "GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01655628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*